Amgen (NASDAQ:AMGN) Price Target Raised to $425.00

Key Points

• Goldman Sachs raised its price target on Amgen to $425 from $415 and kept a "buy" rating, implying roughly a 29% upside from the stock's prior close.
• Amgen beat Q1 expectations with EPS of $5.15 (vs. $4.73 expected) and revenue of $8.62B (vs. $8.58B), and set FY2026 guidance of $21.70–$23.10 EPS and $37.1B–$38.5B revenue.
• Regulatory risk emerged as the FDA proposed withdrawing Tavneos over alleged clinical‑trial data manipulation, posing potential revenue, compliance and reputational downside.

Amgen (NASDAQ:AMGN - Get Free Report) had its price target increased by stock analysts at The Goldman Sachs Group from $415.00 to $425.00 in a research report issued on Friday,MarketScreener reports. The brokerage presently has a "buy" rating on the medical research company's stock. The Goldman Sachs Group's target price indicates a potential upside of 28.92% from the company's previous close.

AMGN has been the topic of several other reports. Wall Street Zen downgraded shares of Amgen from a "buy" rating to a "hold" rating in a research note on Saturday, April 25th. Wells Fargo & Company boosted their price target on shares of Amgen from $375.00 to $390.00 and gave the company an "equal weight" rating in a report on Thursday, March 19th. Leerink Partners reiterated a "market perform" rating and issued a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. Barclays started coverage on shares of Amgen in a report on Friday, February 20th. They issued an "equal weight" rating and a $350.00 price objective for the company. Finally, Guggenheim upped their price objective on shares of Amgen from $347.00 to $351.00 and gave the stock a "neutral" rating in a report on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Amgen presently has a consensus rating of "Hold" and an average price target of $357.00.

Amgen Price Performance

Amgen stock traded down $16.60 during mid-day trading on Friday, hitting $329.65. The company's stock had a trading volume of 675,699 shares, compared to its average volume of 2,705,582. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock has a market capitalization of $177.91 billion, a P/E ratio of 23.22, a P/E/G ratio of 3.34 and a beta of 0.47. Amgen has a twelve month low of $261.43 and a twelve month high of $391.29. The stock's fifty day moving average price is $358.07 and its two-hundred day moving average price is $340.45.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.73 by $0.42. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $8.62 billion for the quarter, compared to analysts' expectations of $8.58 billion. During the same period in the previous year, the company posted $4.90 EPS. The company's quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts forecast that Amgen will post 22.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AMGN. Robeco Institutional Asset Management B.V. increased its stake in shares of Amgen by 10.0% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company's stock worth $157,584,000 after purchasing an additional 43,884 shares during the last quarter. Sequoia Financial Advisors LLC increased its stake in shares of Amgen by 2.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company's stock worth $45,334,000 after purchasing an additional 3,619 shares during the last quarter. Curtis Advisory Group LLC acquired a new position in shares of Amgen during the 4th quarter worth about $1,669,000. Davis Capital Management acquired a new position in shares of Amgen during the 3rd quarter worth about $1,841,000. Finally, D.A. Davidson & CO. increased its stake in shares of Amgen by 2.6% during the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company's stock worth $68,590,000 after purchasing an additional 6,222 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat Wall Street: EPS $5.15 vs. $4.73 expected and revenue $8.62B vs. $8.58B expected, signaling near-term topline and profit resilience. Amgen (AMGN) Q1 Earnings and Revenues Beat Estimates
• Positive Sentiment: Product sales rose ~4%, driven by strength in cholesterol and rare-disease medicines; management highlighted momentum in six growth drivers and advancement of the MariTide weight‑loss program. Amgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug
• Neutral Sentiment: Company set FY2026 EPS guidance of $21.70–$23.10 and revenue range $37.1B–$38.5B; the EPS range straddles consensus, so guidance reduces uncertainty but doesn't clearly raise the bar. AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
• Neutral Sentiment: Full earnings call and transcripts are available for investors to assess management commentary on pipeline timing, biosimilars and margin outlook. Amgen Inc. (AMGN) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Regulatory risk: the FDA proposed withdrawing Tavneos after alleging clinical-trial data manipulation and false statements in the approval process — this raises potential revenue, compliance and reputational risks if actions proceed. FDA Tavneos Proposal Puts Amgen’s Data Integrity And Oversight In Focus

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.